You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The company expects to offer 6.7 million common shares at a maximum offering price of $16 per share.
FLX Bio will apply Personalis' ImmunoID Next platform as part of a Phase I/II clinical trial evaluating its FLX475 drug in cancer therapy.
The ACE ImmunoID test uses exome and transcriptome sequencing to identify neoantigens for the development of personalized cancer vaccines.
The contract was awarded as part of the VA's Precision Oncology Program, which aims to provide advanced clinical care and generate cancer biomarker data.
The company, which first signed on to provide services to the VA's Million Veteran Program in 2013, will provide the department with 34,000 more genomes.
The firm has received approval for two unspecified clinical tests, with a permit under the molecular genetic testing category.
Researchers compared three open source annotation tools, and also looked at correspondence with public databases, identifying a number of stumbling blocks.
The companies will use Personalis' ACE ImmunoID next-generation sequencing platform to analyze tumor samples from clinical trials of Argos' drug.
The company has been working with the VA since 2013, when it it received a contract to provide sequencing and data analysis for enrollees in the Million Veteran Program.
The companies have signed a letter of intent to offer Personalis' next-generation tumor sequencing and interpretation technology to customers in Canada.
The Los Angeles Times reports that experts say Moderna's investigational COVID-19 vaccine results seem to be a step in the right direction, but that more testing is needed.
The Washington Post reports a new coronavirus data reporting protocol goes around the Centers for Disease Control and Prevention.
The Trump Administration has reversed its policy that could have stripped international students of their visas, the New York Times says.
In Cell this week: proteomic and metabolomic analysis of blood from COVID-19 patients, change in phosphorylation with infection, and more.